

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Bronchopulmonary Dysplasia

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 18 | 2026

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.



www.dgai.de



www.ai-online.info

**Bisher in A&I publizierte
Handlungsempfehlungen finden
Sie unter:**

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

**Dr. med. Christine Gaik,
DESAIC, FESAIC**

Oberärztin
Klinik für Anästhesie und
Intensivtherapie
Universitätsklinikum Gießen
und Marburg GmbH,
Standort Marburg
Baldingerstraße
35033 Marburg, Deutschland
E-Mail:
gaikc@med.uni-marburg.de

**Priv.-Doz. Dr. med.
Philipp Gude, MHBA**

Geschäftsführender Oberarzt
Klinik für Anästhesiologie und
Intensivmedizin
Universitätsklinikum
St. Elisabeth-Hospital
Bleichstraße 15
44787 Bochum, Deutschland
E-Mail:
philipp.gude@ruhr-uni-bochum.de

orphan**a**nesthesia

Anesthesia recommendations for Bronchopulmonary Dysplasia

Disease name: Bronchopulmonary Dysplasia

ICD 10: P27.1

Synonyms: Chronic lung disease of prematurity

Disease summary:

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that remains one of the most prevalent long-term sequelae of premature birth. Northway and colleagues first described the condition in 1967 after 32 preterm infants (mean gestational age 34 weeks) with respiratory distress syndrome developed characteristic radiographic changes following the initiation of positive pressure mechanical ventilation [1]. Four stages of lung injury were described in "classic" BPD: exudative (age 1-3 days); necrosis and early repair (age 4-10 days); microcyst formation and pulmonary fibrosis (age 10-12 days); and severe cystic changes and cor pulmonale (after 30 days of age) [2]. The clinical definition of BPD has evolved with time and advancements in neonatal care including surfactant therapy, antenatal steroid administration, and improved ventilator strategies [3-5]. Most infants currently developing BPD are born at less than 29 weeks gestational age, during the time of canalicular and saccular development [5,6]. "New" BPD is characterized by uniform arrest of lung development, with simplified alveolar structures and dysmorphic capillaries. These infants are more likely to present with a mild respiratory distress syndrome and a continued need for supplemental oxygen [5-7]. Three levels of BPD severity are determined at 36 weeks post-menstrual age (gestational age plus time elapsed from birth) based on supplemental oxygen and positive pressure requirements [8-10]. Long-term BPD survivors may experience persistent airway obstruction and pulmonary hypertension, complicating anaesthetic management.

► **Citation:** Vadi M, Malkin M, Lauer R: Bronchopulmonary Dysplasia. *Anästh Intensivmed* 2026;67:S210–S220.
DOI: 10.19224/ai2026.S210

Diagnosis may be incorrect; if uncertainty exists, the diagnosis should be re-evaluated.

Every patient is unique; individual circumstances must always guide clinical care.

Medicine is in progress; new clinical knowledge may not be yet reflected in this guideline Perhaps new knowledge.



Recommendations are not rules or laws; they provide a framework to support clinical decision-making. Although this recommendation has passed a structured review process, it does not meet the formal criteria of a guideline.

Translations may not always reflect the most recent updates of the English version.



Find more information on the disease, its centers of reference and patient organizations on Orphanet: www.orpha.net

Emergency information

A	AIRWAY / ANESTHETIC TECHNIQUE	No direct correlation with difficult tracheal intubation. Risk of subglottic stenosis, airway granulomas, and pseudopolyps if prolonged intubation occurred during infancy. No definite recommendation for either general or regional anesthesia.
B	BLOOD PRODUCTS (COAGULATION)	Tailor preparation and administration of blood products to the specific surgical procedure. No associated coagulation disorders.
C	CIRCULATION	Anesthetic risk is increased in BPD patients with pulmonary hypertension. Avoid hypoxemia, hypercarbia, and acidosis. Inhaled nitric oxide and cardiac inotropes may be required during a pulmonary hypertensive crisis.
D	DRUGS	Glucocorticoid administration for reactive airway disease may cause adrenal suppression. Assess the need for stress-dose steroid supplementation. Diuretic use may lead to electrolyte imbalances.
E	EQUIPMENT	Oxygen should be available for operating theatre transport. Consider mechanical transport ventilator use for intubated patients requiring positive pressure ventilation to ensure consistent minute ventilation.

Typical surgery and procedures

Procedures addressing sequelae of prematurity include: gastrostomy tube placement; inguinal hernia repair; ligation of patent ductus arteriosus; ophthalmologic procedures; ventriculoperitoneal shunt placement.

Type of anesthesia

There is no definite recommendation for either general or regional anesthesia.

Long-term BPD survivors experience airway obstruction and hyperreactivity. It is recommended that BPD patients not undergo general anesthesia for elective procedures during an acute respiratory infection; patients should be re-evaluated at least two weeks after full symptom resolution [11]. Existing pulmonary morbidity and procedural needs will determine appropriate airway management (i.e., mask, laryngeal mask airway, or endotracheal tube) [13]. Laryngeal mask airway may decrease bronchospasm risk but does not protect the airway from aspiration [14]. In children with severe BPD and low lung compliance, endotracheal intubation and mechanical ventilation may be required regardless of procedure type [13].

Regional or local anesthesia avoids airway manipulation but may not be feasible for certain sites of surgery or in uncooperative pediatric patients. Avoid spinal anesthesia in patients with severe pulmonary hypertension and right heart strain, as decreased venous return and bradycardia may precipitate right heart failure.

Necessary additional pre-operative testing (beside standard care)

A thorough medical history must be obtained. For BPD infants requiring surgery while on the neonatal unit, determine the anesthetic history, current medications, allergies, cough or sputum production, supplemental oxygen requirements, and the extent of positive pressure ventilator support.

Additionally, question parents of BPD patients returning for follow-up procedures after neonatal unit discharge regarding interval hospitalizations (including the need for tracheal intubation), changes in supplemental oxygen requirements, non-invasive positive pressure requirements (ex. CPAP), and exercise tolerance. Poor exercise tolerance may present as diaphoresis or cyanosis during feeding or failure to thrive in patients not yet able to ambulate.

Physical examination should assess vital signs, presence of wheezing or cough, accessory muscle use, cyanosis, and hydration status.

Consider the following testing in patients with persistent disease:

- Electrolyte panel: in patients receiving chronic diuretic therapy
- Arterial blood gas and pulse oximetry: in patients with recent increases in oxygen requirements or in any infant requiring supplementary oxygen
- Chest radiograph
- Echocardiogram: screening for pulmonary hypertension by transthoracic echocardiography is indicated 1) if severe respiratory compromise is present in any preterm infant less than 28 weeks' gestation; 2) in any infant with established BPD at 36

weeks post-menstrual age and before hospital discharge; 3) in any infant with prolonged oxygen requirement, poor growth, or unsatisfactory clinical improvement [15].

- Cardiac catheterization: reserved for BPD patients with pulmonary hypertension by echocardiogram who have (1) unexplained hypoxic respiratory failure or recurrent pulmonary edema; (2) pulmonary hypertension out of proportion to echocardiographic findings; (3) pulmonary hypertension requiring multiple or chronic pulmonary vasodilator therapy; or (4) the presence of persistent shunt lesions [16].

Particular preparation for airway management

BPD has no direct correlation with difficult tracheal intubation. However, BPD patients are at risk for subglottic stenosis, airway granulomas, and pseudopolyps if prolonged tracheal intubation occurred during infancy [17-19]. Smaller tracheal tubes may be required.

Particular preparation for transfusion or administration of blood products

Retrospective studies have shown correlations between the receipt of blood transfusions and the development of BPD in very low-birth weight infants [20-22], possibly due to iron-induced oxidative stress [23]. However, there is no clear evidence for a causal relationship based on a 2023 systematic review and meta-analysis [24].

Patients with known BPD may require diuretic administration in conjunction with transfusion to avoid pulmonary edema and worsening hypoxemia.

Particular preparation for anticoagulation

There is no evidence to support the need of particular anticoagulation.

Particular precautions for positioning, transportation and mobilization

Avoid hypothermia, hypoxia, and hypercarbia as these factors may worsen pulmonary hypertension and precipitate right ventricular failure. Oxygen should be made available for operating theatre transport. As ineffective bag ventilation may result in hypercapnia, consider mechanical transport ventilator use for intubated patients to ensure consistent minute ventilation.

Interactions of chronic disease and anesthesia medications

Post-natal systemic or inhaled corticosteroids are administered by some centers to reduce inflammation and improve lung function in infants with evolving or established BPD [5,6,23,25]. Long-term BPD survivors may receive oral, intravenous, or inhaled steroids as treatment for severe reactive airway disease in the outpatient setting. All routes of

glucocorticoid administration (oral, inhaled, intranasal, topical, intramuscular, and intravenous) have been associated with suppression of the hypothalamic-pituitary-adrenal axis [26,27]. Physiologic stress including injury, surgery, or severe infection may precipitate adrenal crisis. Consider adrenal suppression in patients with a history of exogenous steroid use and unexplained hypotension or hypoglycemia under anesthesia. Administer stress-dose glucocorticoid supplementation in patients who are on long-standing oral steroid therapy (greater than 8-12 mg/m²/day for greater than 2 weeks), or those who have discontinued steroid use within the last 6 months [28].

Anesthetic procedure

Anesthetic management goals include avoidance of bronchoconstriction, elevations in pulmonary vascular resistance, or decreases in cardiac contractility. Propofol is a bronchodilator and is a useful induction agent in the hemodynamically stable patient with reactive airway disease. This agent should be used with caution in patients with pulmonary hypertension, as large boluses can significantly decrease systemic vascular resistance and impair biventricular function [28].

Ketamine maintains arterial pressure and systemic vascular resistance while simultaneously enhancing bronchodilatation. It is useful in the hemodynamically unstable and actively wheezing patient requiring emergency surgery. Ketamine administration in children with pulmonary hypertension was previously controversial, as some studies suggested its use may increase pulmonary vascular resistance [29-31]. More recent studies show that ketamine has minimal impact on hemodynamics in children with congenital heart disease and/or pulmonary hypertension when used at usual clinical doses [32,33].

Volatile agents decrease hypoxic pulmonary vasoconstriction. Sevoflurane is preferable for inhalational inductions due to its bronchodilating effects as well as an association with a decreased incidence of laryngospasm and cardiac arrhythmias when compared to other volatile agents. Carefully titrate volatile agents in patients with pulmonary hypertension, as their use may result in a dose-dependent depression of cardiac contractility and systemic vascular resistance [28].

Tracheal intubation may precipitate bronchospasm. Consider avoiding tracheal intubation by using a mask or supraglottic airway device for appropriate cases [13]. Ensure a deep level of anesthesia before airway manipulation. Deep extubation reduces the risk of bronchospasm from coughing on the tracheal tube but does not protect the patient from aspiration or laryngospasm [28]. Regional anesthesia avoids airway manipulation but is not appropriate for all sites of surgery. Avoiding histamine-releasing neuromuscular blocking agents in patients with BPD is advisable. Acetylcholinesterase inhibitors need to be used with caution during reversal of neuromuscular blockade due to the risk of bronchospasm. Sugammadex reverses rocuronium- and vecuronium-induced neuromuscular blockade rapidly without muscarinic side effects [34,35].

Particular or additional monitoring

Monitor pulse oxygen saturation, end tidal carbon dioxide, and body temperature to avoid hypoxia, hypercarbia, and hypothermia. These factors may worsen pulmonary hypertension and lead to right heart failure. Perform arterial blood gas sampling at regular intervals. Consider arterial cannulation for invasive blood pressure monitoring and central venous line placement for inotrope administration in patients with pulmonary hypertension for surgical

cases of increased length or complexity. Monitor neuromuscular blockade and ensure its effects are completely reversed after surgery.

Possible complications

Children with BPD frequently experience wheezing, particularly when exposed to stressful conditions such as exercise. Formerly preterm children with persistent obstructive airway disease have a significantly greater response to bronchodilators after exercising, when compared to preterm and term controls with normal lung function [36,37]. Metered dose inhaler or in-line nebulizer administration of bronchodilators is safe and effective for many BPD patients during acute bronchospasm [38]. Refractory bronchospasm may require IV terbutaline or epinephrine administration as a last resort.

In patients with pulmonary hypertension, avoid increases in pulmonary vascular resistance to prevent a pulmonary hypertensive crisis. Moderate hyperventilation with 100% oxygen, correction of acidosis, improved analgesia, and the administration of pulmonary vasodilators are useful in this setting. Inhaled nitric oxide decreases pulmonary vascular resistance without significant systemic effects. Inotropic support is considered for persistent systemic hypotension despite pulmonary vasodilator therapy [28].

Post-operative care

The degree of post-operative monitoring is dependent on the surgical procedure and the physical condition of the patient. Intensive care unit admission may be required for patients experiencing pulmonary hypertensive crisis or requiring mechanical ventilation. Prolonged post-operative ventilation may promote ventilator-associated lung injury and should be avoided.

Disease-related acute problems and effect on anesthesia and recovery

As previously mentioned, bronchospasm and pulmonary hypertensive crisis may complicate both intra- and post-operative care. Moderate- to high-risk patients should have anesthetics performed in facilities with experienced pediatric anesthesiologists and a pediatric intensive care unit capable of managing acute pulmonary hypertensive crises.

Ambulatory anesthesia

Typically avoided. Ambulatory anesthesia is only considered in BPD patients with mild disease (i.e. no baseline wheezing, cyanosis, home oxygen use, or pulmonary hypertension).

Obstetrical anesthesia

Not reported.

References

1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. *N Engl J Med* 1967;276:357-68
2. Northway WH Jr. Bronchopulmonary dysplasia: then and now. *Arch Dis Child* 1990; 65(10 Spec. No.):1076-81
3. Philip AG. Bronchopulmonary dysplasia: then and now. *Neonatology* 2012;102:1-8
4. Maxwell LG, Goodwin SR, Mancuso TJ, et al. Systemic disorders. In: Davis, PJ, Cladis FP, Motoyama EK, eds. *Smith's Anesthesia for Infants and Children*, 8th Ed. Philadelphia: Elsevier Mosby, 2011:1120
5. Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primers* 2019;5(1):78.
6. Gilfillan M, Bhandari A, Bhandari V. Diagnosis and management of bronchopulmonary dysplasia. *BMJ* 2021;375:n1974.
7. Coalson JJ. Pathology of bronchopulmonary dysplasia. *Semin Perinatol* 2006;30:179-84
8. Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary dysplasia: executive summary of a workshop. *J Pediatr* 2018;197:300-308.
9. Jensen EA, Dysart K, Gantz MG, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. *Am J Respir Crit Care Med* 2019 ;200(6):751-59.
10. Katz TA, van Kaam AH, Schuit E, et al. Comparison of new bronchopulmonary dysplasia definitions on long-term outcomes in preterm infants. *J Pediatr* 2023;253:86-93.e4.
11. Stepanovic B, Regli A, Becke-Jakob K, et al. Preoperative preparation of children with upper respiratory tract infection: a focussed narrative review. *BJA* 2024;133(6):1212-21.
12. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics* 2005;116:1353-60
13. Schmidt A and Ramamoorthy C. Bronchopulmonary dysplasia. *Paediatr Anaesth.* 2022;32(2):174-180.
14. Ferrari LR and Goudsouzian NG. The use of the laryngeal mask airway in children with bronchopulmonary dysplasia. *Anesth Analg* 1995;81(2):310-3
15. Hansmann G, Sallmon H, Roehr CC, et al.; European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. *Pediatr Res* 2021;89(3):446-455.
16. El-Saie A, Varghese NP, Webb MK, et al. Bronchopulmonary dysplasia - associated pulmonary hypertension: An updated review. *Semin Perinatol* 2023;47(6):151817.
17. Doull IJ, Mok Q, Tasker RC. Tracheobronchomalacia in preterm infants with chronic lung disease. *Arch Dis Child Fetal Neonatal Ed* 1997;76:F203-5
18. Duncan S, Eid N. Tracheomalacia and bronchopulmonary dysplasia. *Ann Otol Rhinol Laryngol* 1991;100:856-8
19. Miller RW, Woo P, Kellman RK, Slagle TS. Tracheobronchial abnormalities in infants with bronchopulmonary dysplasia. *J Pediatr* 1987;111:779-82
20. Hernandez-Ronquillo L, Tellez-Zenteno JF, Weder-Cisneros, N, et al. Risk factors for the development of bronchopulmonary dysplasia: a case-control study. *Arch Med Res* 2004;35:549-53
21. Zhang H, Fang J, Su H, et al. Risk factors for bronchopulmonary dysplasia in neonates born at ≤ 1500 g (1999-2009). *Pediatr Int* 2011;53:915-20
22. Collard KJ. Transfusion related morbidity in premature babies: possible mechanisms and implications for practice. *World J Clin Pediatr* 2014;3(3):19-29

23. Doyle LW, Ehrenkranz RA, Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database Syst Rev* 2014; 5:CD001146
24. Tang L, Zhu TT, Zhao J. Association between red blood cell transfusion and bronchopulmonary dysplasia: a systematic review and meta-analysis. *Front Pediatr* 2023;11:1095889.
25. Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. *Cochrane Database Syst Rev* 2014; 5:CD001145
26. Bancos I, Hahner S, Tomlinson J, et al. Diagnosis and management of adrenal insufficiency. *Lancet Diabetes Endocrinol* 2015;3(3):216-26
27. Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. *Allergy Asthma Clin Immunol* 2011;7:13
28. Lauer R, Vadi M, Mason L. Anaesthetic management of the child with co-existing pulmonary disease. *Br J Anaesth* 2012;109(S1):i47-i59
29. Morray JP, Lynn AM, Stamm SJ, et al. Hemodynamic effects of ketamine in children with congenital heart disease. *Anesth Analg* 1984;63:895-9
30. Berman W Jr, Fripp RR, Rubler M, et al. Hemodynamic effects of ketamine in children undergoing cardiac catheterization. *Pediatr Cardiol* 1990; 11:72-6
31. Wolfe RR, Loehr JP, Schaffer MS, et al. Hemodynamic effects of ketamine, hypoxia and hyperoxia in children with surgically treated congenital heart disease residing greater than or equal to 1,200 meters above sea level. *Am J Cardiol* 1991;67:84-7
32. Loomba RS, Gray SB, Flores S. Hemodynamic effects of ketamine in children with congenital heart disease and/or pulmonary hypertension. *Congenit Heart Dis* 2018;13(5):646-654.
33. Williams GD, Maan H, Ramamoorthy C, et al. Perioperative complications in children with pulmonary hypertension undergoing general anesthesia with ketamine. *Paediatr Anaesth* 2010 ;20(1):28-37.
34. Won YJ, Lim BG, Lee DK, et al. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: A systematic review and meta-analysis. *Medicine (Baltimore)* 2016;95(34):e4678.
35. Voss T, Wang A, DeAngelis M, Speek M, et al. Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study. *Paediatr Anaesth* 2022;32(3):436-445.
36. Cousins M, Hart K, Williams EM, et al. Impaired exercise outcomes with significant bronchodilator responsiveness in children with prematurity-associated obstructive lung disease. *Pediatr Pulmonol* 2022;57(9):2161-2171.
37. Joshi S, Powell T, Watkins WJ, et al. Exercise-induced bronchoconstriction in school-aged children who had chronic lung disease in infancy. *J Pediatr* 2013;162(4):813-818.e1.
38. Hingston CD, Homes TW, Wise MP. Airway emergency during anaesthesia using a metered dose inhaler—III. *Anaesthesia* 2011;66(6):531.

Date last modified: **December 2025**

This recommendation has been prepared in 2016 by:

Author(s)

Marissa Vadi, Anesthesiologist, Loma Linda University, Loma Linda, California, USA

Mathew Malkin, Anesthesiologist, Loma Linda University, Loma Linda, California, USA

Ryan Lauer, Anesthesiologist, Loma Linda University, Loma Linda, California, USA
rlauer@llu.edu

Disclosure: The author(s) has no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewer 1

Anne Greenough, Neonatal intensive care unit, King's College Hospital, London, United Kingdom
anne.greenough@kcl.ac.uk

Reviewer 2

Kathleen M Deakins, Pediatric Respiratory Care, Rainbow Babies and Children's Hospital, Cleveland OH, USA
kathleen.deakins@uhhospitals.org

Disclosure: The reviewer(s) have no financial or other competing interest to disclose.

Update and revision (2025)

Marissa Vadi, Anesthesiologist, University of California, Davis, Sacramento, California, USA
mgvadi@health.ucdavis.edu

Mathew Malkin, Anesthesiologist, University of California, Davis, Sacramento, California, USA
mrmalkin@health.ucdavis.edu

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewer

Beate Küppers, Anesthesiologist, University Hospital Pisa, Italy

Disclosure The reviewer has no financial or other competing interest to disclose.

Editorial Review

Christine Gaik, Anesthesiologist, Department of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, Campus Marburg and Philipps University of Marburg, Germany
gaikc@med.uni-marburg.de

Herausgeber



DGAI

Deutsche Gesellschaft
für Anesthesiologie und
Intensivmedizin e. V.
Präsident: Prof. Dr. G. Marx,
Aachen



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e. V.
Präsidentin: Prof. Dr.
G. Beck, Mannheim

Schriftleitung

Präsident/in der Herausgeberverbände

Gesamtschriftleiter/Editor-in-Chief:

Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt

Stellvertretender Gesamtschriftleiter/

Deputy Editor:

Prof. Dr. T. Volk, Homburg/Saar

CME-Schriftleiter/CME-Editor:

Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Priv.-Doz. Dr. E. Adam, Frankfurt

Prof. Dr. M. Adamzik, Bochum

Dr. J. Aulenkamp, Essen

Prof. Dr. G. Beck, Mannheim

Prof. Dr. T. Brenner, Essen

Prof. Dr. A. Brinkmann, Heidenheim

Prof. Dr. M. Coburn, Bonn

Prof. Dr. S.M. Coldewey, Zürich

Prof. Dr. V. von Dossow, Bad Oeynhausen

Prof. Dr. B. Ellger, Dortmund

Prof. Dr. K. Engelhard, Mainz

Prof. Dr. M. Fischer, Göttingen

Prof. Dr. D. Fries, Innsbruck

Prof. Dr. J.-T. Gräsner, Kiel

Prof. Dr. K. Hahnenkamp, Greifswald

Prof. Dr. A.R. Heller, Augsburg

Prof. Dr. B. Jungwirth, Ulm

Prof. Dr. T. Loop, Freiburg

Prof. Dr. K. Meissner, Göttingen

Prof. Dr. W. Meißner, Jena

Prof. Dr. P. Meybohm, Würzburg

Prof. Dr. T. Müller-Wolff, Ludwigsburg

Prof. Dr. H. Mutlak, Offenbach

Prof. Dr. C. Nau, Lübeck

Prof. Dr. V. Neef, Frankfurt

Prof. Dr. B. O'Brien, Berlin

Dr. B. Oehler, Heidelberg

Prof. Dr. S.G. Sakka, Koblenz

Prof. Dr. M. Sander, Gießen

Prof. Dr. B. Saugel, Hamburg

Prof. Dr. S. Schäfer, Oldenburg

Priv.-Doz. Dr. H. Schöchl, Salzburg

Prof. Dr. A. Steinbicker, Köln

Dr. M.T. Völker, Leipzig

Prof. Dr. N.-M. Wagner, Würzburg

Prof. Dr. F. Wappler, Köln

Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Korrespondenzadresse:

Neuwieder Straße 9 | 90411 Nürnberg |

Deutschland | Tel.: 0911 9337812

E-Mail: redaktion@ai-online.info

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |

97500 Ebelsbach | Deutschland

www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |

Tel.: 09522 9435-0 | Fax: 09522 9435-67

E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Tel.: 09522 9435-70

E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler

Neuwieder Straße 9 | 90411 Nürnberg

Tel.: 0171 9432534

E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Robert Kux | Tel.: 09522 9435-71

E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Roland Mehl

3D Arts GmbH

Dunantstraße 2 | 92224 Amberg

E-Mail: rmehl@3darts.de

www.3darts.de

Erscheinungsweise 2026

Der 67. Jahrgang erscheint 6x pro Jahr
alle zwei Monate, beginnend ab Februar.

**Die A&I ist die Verbandszeitschrift von
DGAI und BDA.**

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Lieferbedingungen

Die allgemeinen Geschäfts- und Lieferbedingungen entnehmen Sie bitte dem Impressum auf www.ai-online.info

Indexed in **CINAHL**; **Current Contents®/Clinical Medicine**; **EBSCO**; **EMBASE/Excerpta Medica**; **Medical Documentation Service**; **Research Alert**; **Sci Search**; **Scopus**; **SUBIS Current Awareness in Biomedicine**; **VINITI**; **Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urheberrechtlich geschützt. Jegliche Art von Vervielfältigungen – sei es auf mechanischem, digitalem oder sonst möglichem Wege – bleibt vorbehalten. Die Aktiv Druck & Verlags GmbH ist allein autorisiert, Rechte zu vergeben und Sonderdrucke für gewerbliche Zwecke, gleich in welcher Sprache, herzustellen. Anfragen hierzu sind nur an den Verlag zu richten. Jede im Bereich eines gewerblichen Unternehmens zulässig hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG. Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, dass solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürfen.

Wichtiger Hinweis

Für Angaben über Dosierungsanweisungen und Applikationsformen kann vom Verlag und den Herausgebern keine Gewähr übernommen werden. Derartige Angaben müssen vom jeweiligen Anwender im Einzelfall anhand anderer Literaturstellen auf ihre Richtigkeit überprüft werden. Gleiches gilt für berufs- und verbandspolitische Stellungnahmen und Empfehlungen.

Der Verlag veröffentlicht die Beiträge in der von den Autorinnen und Autoren gewählten Genderform.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu